About Phaseolus vulgaris Extract (Phase 2 Carb Controller)
White kidney bean extract (Phaseolus vulgaris L.) is a botanical alpha-amylase inhibitor marketed as a 'carb blocker' or 'starch neutralizer'; the dominant standardized form is Phase 2 / Phase 2 Carb Controller (Pharmachem), standardized by alpha-amylase-inhibiting units rather than by mg. Mechanism: it inhibits pancreatic alpha-amylase, slowing starch breakdown and reducing the glycemic/caloric load from starchy meals. The clinical reality is more modest than the marketing: two meta-analyses converge on a real but small weight effect (~1-1.6 kg over 1-3 months) and a fat-mass reduction, but the largest dataset is manufacturer-funded and non-proprietary extracts have failed to show significant weight loss — indicating benefit is tied to standardized inhibitory activity, not white-bean mass per se. It is dose- and timing-dependent (taken with starch-heavy meals), and there is no robust evidence it improves fasting glucose or HbA1c in non-diabetics. No established RDA/UL.
What Phaseolus vulgaris Extract (Phase 2 Carb Controller) supports
- Modest weight and fat-mass reduction (~1-1.6 kg over 1-3 months) in overweight adults
- Inhibits alpha-amylase to slow starch digestion and lower the caloric load from carb-heavy meals
- Backed by two RCT meta-analyses, though effects are small and the best data uses the standardized Phase 2 form
How much Phaseolus vulgaris Extract (Phase 2 Carb Controller) to take
The RDA prevents deficiency. The effective range is what clinical trials used to actually move the outcome.
Effective
1000–3000
mg
Trials used 400-3,000 mg/day of standardized aqueous extract (Phase 2) with starch-containing meals; the 2018 meta-analysis most commonly used 3,000 mg/day, while a 2024 RCT showed dose-dependent loss at 700-1,000 mg/day. Phase 2 is standardized to alpha-amylase-inhibiting units, so for non-proprietary extracts mg is a weak proxy because activity, not mass, drives effect. Range reflects RCT doses, not label DV.
Clinical evidence
Moderate clinical evidence. Two meta-analyses (2018 manufacturer-funded n=573; independent n=543) plus a 2024 RCT converge on a small weight effect (~1-1.6 kg over 1-3 months) and fat-mass reduction, but the strongest dataset is industry-funded with heterogeneity/quality concerns, non-proprietary extracts failed to reach significance for weight, and there is no robust glucose/HbA1c benefit in non-diabetics
NIH Fact Sheet